Global $172.8 Bn End Stage Renal Disease Markets, 2021-2027 by Disease Type, Treatment Type, End User, Geography, Competitive Analysis - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Global End Stage Renal Disease Market (2021-2027) by Disease Type, Treatment Type, End User, and Geography. IGR Competitive Analysis, Impact of Covid-19, Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
The Global End Stage Renal Disease Market is estimated to be USD 83 Bn in 2021 and is expected to reach USD 172.8 Bn by 2027, growing at a CAGR of 13%.
The increasing number of patients suffering from kidney failure and the introduction of technologically advanced products, such as low maintenance dialysis equipment and artificial kidney, are the major factors expected to drive the end stage renal disease (ESRD) market. The ongoing Covid-19 pandemic has resulted in an increased demand for home dialysis across the globe.
- By Disease Type, the market is classified as Chronic Kidney Disease and End stage renal disease.
- By Treatment, the market is classified as Dialysis, Medication and kidney transplantation. Dialysis is more convenient and easier to obtain for a patient with ESRD and the whole process can be done at a dialysis center or at home.
- By End User, the market is classified as Dialysis centers, hospitals, clinics and research and academic institutes.
- By Geography, Asia Pacific is projected to lead the market.
- Nipro Corporation
- Fresenius Medical Care AG & Co. KGaA
- Baxter International, Inc.
- Medtronic Plc
- B. Braun Melsungen AG
- Asahi Kasei Medical Co., Ltd.
- Cantel Medical
- Nikkiso Co., Ltd.
- JMS Co. Ltd.
- Amgen Inc.
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd
- Fresenius Medical Care AG & Co.
- GlaxoSmithKline PLC
- Keryx Biopharmaceuticals, Inc
- Kissei Pharmaceutical Co., Ltd
- Novartis AG
- Pfizer Inc.
- Sanofi SA
- Teva Pharmaceutical Industries Ltd
Key Topics Covered:
1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.4 Years Considered
1.6 Key Stakeholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.3 Market Size Estimation
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
4 Market Overview
4.2 Market Dynamics
184.108.40.206 Growing prevalence of diabetes and hypertension
220.127.116.11 Introduction of technologically advanced products
18.104.22.168 Increasing number of patients suffering from chronic kidney disease
22.214.171.124 Risk of complications
126.96.36.199 Stringent regulatory policies for dialysis products
188.8.131.52 High Focus on technology
184.108.40.206 Lack of infrastructure availability in emerging countries
5 Market Analysis
5.1 Porter's Five Forces Analysis
5.2 Impact of COVID-19
5.3 Ansoff Matrix Analysis
6 Global End Stage Renal Disease Market, By Disease Type
6.1 Chronic Kidney Disease
6.2 End-Stage Renal Disease (ESRD)
7 Global End Stage Renal Disease Market, By Treatment Type
7.3 Kidney Transplantation
8 Global End Stage Renal Disease Market, By End Users
8.1 Dialysis Centres
8.2 Hospital & Clinics
8.3 Research and Academic Institutes
9 Global End Stage Renal Disease Market, By Geography
9.2 North America
9.3 South America
9.4.6 Rest of Europe
9.5.6 South Korea
9.5.9 Rest of APAC
9.6 Rest of the World
9.6.2 Saudi Arabia
9.6.3 South Africa
9.6.4 United Arab Emirates
9.6.5 Latin America
10 Competitive Landscape
10.1 Competitive Quadrant
10.2 Market Share Analysis
10.3 Competitive Scenario
10.3.1 Mergers & Acquisitions
10.3.2 Agreement, Collaborations, & Partnerships
10.3.3 New Product Launches & Enhancements
10.3.4 Investments & Funding
11 Company Profiles
For more information about this report visit https://www.researchandmarkets.com/r/n6fkaf
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900